Radical cystectomy with urinary diversion is one of the most complex urologic procedures and is associated with significant morbidity and mortality. Although it remains the gold standard for treatment of…
At present, radical cystectomy is a mainstay in the management of all bladder cancers, whether of conventional urothelial histology or variant. However, in the case of some variants, it is…
Non–muscle-invasive bladder cancer is a highly recurrent disease. The health care costs for non–muscle-invasive bladder cancer are a major burden for society. Bladder cancer treatment starts with a presumed complete…
Bladder cancer (BCa) is a heterogeneous disease with a variable natural history. Most patients (70%) present with superficial tumors (stages Ta, T1, or carcinoma in situ). However, 3 out of…
Classic as well as more recent large-scale genomic analyses have uncovered multiple genes and pathways important for bladder cancer development. Genes involved in cell-cycle control, chromatin regulation, and receptor tyrosine…
Bladder cancer incidence is higher in old men, shows geographic variation, and is mostly an environmental disease. Cigarette smoking, occupational exposures, water arsenic, Schistosoma haematobium infestation, and some medications are…
Joaquim Bellmunt, MD, PhD, Editor After very little advancement in the last two decades, bladder cancer is back in the spotlight with the advent of new immunotherapy approaches and the…
The availability of anticomplement therapies has been a major achievement for medicine in the last decade. Indeed, eculizumab has changed the treatment paradigm of paroxysmal nocturnal hemoglobinuria and atypical hemolytic…
Thrombotic microangiopathies (TMA) such as atypical hemolytic uremic syndrome (aHUS) have evolved from rare, fulminant childhood afflictions to uncommon diseases with acute and chronic phases involving both children and adults….
